Charles River Laboratories International Inc (CRL) Actualités

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before...

Charles River Provides Translational Expertise at Neuroscience 2024

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous...

Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

As part of the DanubeNeuro program, Charles River and CEBINA will accelerate innovative approaches to treating neurodegenerative...

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing...

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International...

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Charles River Laboratories Announces Second-Quarter 2024 Results

– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities